Associations Between ABCC2 Polymorphisms and Cisplatin Disposition and Efficacy

Effect of ABCC2 (MRP2) Transport Function on Erythromycin Metabolism

(2011) R M Franke et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Disruption of multidrug and toxin extrusion MATE1 potentiates cisplatin-induced nephrotoxicity

(2010) Takanori Nakamura et al.   BIOCHEMICAL PHARMACOLOGY

Cisplatin-Induced Downregulation of OCTN2 Affects Carnitine Wasting

(2010) C. S. Lancaster et al.   CLINICAL CANCER RESEARCH

Association of ABCC2 polymorphisms with platinum-based chemotherapy response and severe toxicity in non-small cell lung cancer patients

(2010) Baohui Han et al.   LUNG CANCER

MRP2 and GSTP1 polymorphisms and chemotherapy response in advanced non-small cell lung cancer

(2009) Ning Sun et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Contribution of Organic Cation Transporter 2 (OCT2) to Cisplatin-Induced Nephrotoxicity

(2009) K K Filipski et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

The 5'-Untranslated Region of Multidrug Resistance Associated Protein 2 (MRP2; ABCC2) Regulates Downstream Open Reading Frame Expression through Translational Regulation

(2009) Y. Zhang et al.   MOLECULAR PHARMACOLOGY

Non-response to antiepileptic pharmacotherapy is associated with the ABCC2 −24C>T polymorphism in young and adult patients with epilepsy

(2009) Mike Ufer et al.   Pharmacogenetics and Genomics

Interaction of Cisplatin with the Human Organic Cation Transporter 2

(2008) K. K. Filipski et al.   CLINICAL CANCER RESEARCH

Pharmacogenetic Pathway Analysis of Docetaxel Elimination

(2008) SD Baker et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Influence of genetic polymorphisms on intestinal expression and rifampicin-type induction of ABCC2 and on bioavailability of talinolol

(2008) Sierk Haenisch et al.   Pharmacogenetics and Genomics